Soligenix

Historical price data

Soligenix, Inc. is a late-stage biopharmaceutical company with a bifurcated strategy targeting high-value niches. Its mission is to develop and commercialize novel therapies for rare diseases with significant unmet medical needs, particularly in cutaneous T-cell lymphoma and oral mucositis, while leveraging U.S. government funding to advance a portfolio of biodefense countermeasures. The company's key achievements include positive Phase 3 results for its lead asset, SGX301, and the receipt of multiple government grants and contracts supporting its public health pipeline. Soligenix's strategy is to de-risk development through non-dilutive government funding, advance its late-stage clinical assets toward regulatory submissions, and seek strategic partnerships for commercialization.

Proprietary platforms include Synthetic Hypericin Photodynamic Therapy for targeted oncology, Innate Defense Regulators for immunomodulation, and a Thermostabilization Technology enabling cold-chain-independent vaccines and biologics.

In CTCL, SGX301's key differentiator is its safety profile versus DNA-damaging UV therapies. In oral mucositis, it faces no approved pharmacologic competitors, aiming to be first-in-class. In biodefense, competition is limited but success hinges on meeting specific government procurement needs, where its thermostability platform is a key advantage.